(Q36319439)

13 August 2017

1 reference

title

Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs (English)

1 reference

13 August 2017

Gregory K Bergey

1

1 reference

13 August 2017

language of work or name

1 reference

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

46 Suppl 9

1 reference

13 August 2017

page(s)

161-168

1 reference

Increased rate of major malformations in offspring exposed to valproate during pregnancy

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Neuropsychological effects of exposure to anticonvulsant medication in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Pregabalin as adjunctive therapy for partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Clinical trials for treatment of primary generalized epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Myoclonic status epilepticus following high-dosage lamotrigine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Patients' versus caregivers' report of poor memory in relation to dementia and tested abilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Exacerbation of juvenile myoclonic epilepsy with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Levetiracetam treatment of idiopathic generalised epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Topiramate monotherapy for childhood absence seizures: an open label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Zonisamide for West syndrome: a comparison of clinical responses among different titration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Zonisamide for absence seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Tiagabine-induced absence status in idiopathic generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

Double-Blind, Placebo-Controlled, Lamotrigine in Treatment-Resistant Generalised Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2005.00328.X

10.1111/J.1528-1167.2005.00328.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference